• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    enGene Holdings Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

    6/10/25 5:26:39 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ENGN alert in real time by email
    false000198084500019808452025-06-102025-06-100001980845us-gaap:CommonClassAMember2025-06-102025-06-100001980845engn:CommonSharesMember2025-06-102025-06-10

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): June 10, 2025

    enGene Holdings Inc.
    (Exact name of registrant as specified in its charter)


    British Columbia
     
    001-41854
     
    00-0000000
    (State or other jurisdiction
    of incorporation)
     
    (Commission
    File Number)
     
    (IRS Employer
    Identification No.)

    4868 Rue Levy, Suite 220
    Saint-Laurent, Quebec
     
    H4R 2P1
    (Address of principal executive offices)
     
    (Zip code)

    Registrant's telephone number, including area code (514) 332-4888

    Not Applicable
    (Former Name or Former Address, if Changed Since Last Report)

    Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Shares
    ENGN
    NASDAQ
    Warrants, each exercisable for one Common Share, at an exercise price of $11.50 per Common Share
    ENGNW
    NASDAQ

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒


    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
    Approval of the enGene Holdings Inc. 2025 Employee Stock Purchase Plan
    As described in Item 5.07 of this Current Report on Form 8-K, on June 10, 2025, at its 2025 Annual General Meeting of shareholders (the “Annual Meeting”), the shareholders of enGene Holdings Inc. (the “Company”) approved the adoption of the 2025 Employee Stock Purchase Plan  (the “ESPP”), pursuant to which 2,000,000 common shares of the Company, no par value (the “Common Shares”), will be reserved for issuance.
    The ESPP is intended to promote the interests of the Company by providing eligible employees with the opportunity to acquire a proprietary interest in the Company through participation in an employee stock purchase plan designed to qualify under Section 423 of the Internal Revenue Code of 1986 (the “Code”) for one or more specified offerings made under the Plan, or where determined appropriate by the Plan Administrator under Section 3(b), outside the requirements of Code Section 423. The number of Common Shares reserved for issuance under the ESPP will be limited to 2,000,000 shares. The shares issuable under the ESPP will be made available from authorized but unissued common shares. Shares that are cancelled, terminated, forfeited, fail to vest, or for any other reason are not paid or delivered under the ESPP will generally be available for subsequent offering periods under the ESPP. The Plan is effective as of June 10, 2025, which was the date of the Annual Meeting.
    For a further description of the terms and conditions of the ESPP, as approved by shareholders, see “Proposal 2: Approval of the 2025 Employee Stock Purchase Plan Proposal” in the Company’s definitive Proxy Statement, as filed with the Securities and Exchange Commission on May 9, 2025 (the “Proxy Statement”), which description is incorporated herein by reference.
    The foregoing description of the ESPP, including the description contained in the Proxy Statement, is qualified in its entirety by reference to the full text of the ESPP, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
    Item 5.07. Submission of Matters to a Vote of Security Holders.
    The Annual Meeting of the Company was held on June 10, 2025 at 8:30 a.m. EDT. A total of 38,101,263 of the Company’s  Common Shares were present or represented by proxy at the Annual Meeting, representing approximately 74.60% of the Company’s 51,070,851 Common Shares that were outstanding and entitled to vote at the Annual Meeting as of the record date of April 29, 2025.
    Set forth below, and pursuant to the requirements set out in subsection 11.3 of National Instrument 51-102, are the final voting results for each of the matters submitted to a vote of the shareholders at the Annual Meeting, which matters are each described in further detail in the Company’s Proxy Statement:
    Proposal 1 – Election of Directors


                 
    Director Nominee
     
    For
     
    Withhold
     
    Broker Non-Votes
    Gerald Brunk
     
    30,481,847
     
    8,154
     
    7,611,262
    Dr. Richard Glickman
     
    26,312,872
     
    4,177,129
     
    7,611,262

    Proposal 2 – Approval of the enGene Holdings Inc. 2025 Employee Stock Purchase Plan


                 
    For
     
    Against
     
    Abstain
     
    Broker Non-Votes
    30,152,713
     
    8,427
     
    328,861
     
    7,611,262
    Proposal 3 – Appointment and Remuneration of Auditor


    For
     
    Withhold
     
    Broker Non-Votes
    38,101,229
     
    34
     
    -

    Item 9.01. Financial Statements and Exhibits.
    (d) Exhibits
     
         
    Exhibit Number
      
    Description
       
    10.1
      
    enGene Holdings Inc. 2025 Employee Stock Purchase Plan
       
    104
      
    Cover Page Interactive Data File (Formatted as Inline XBRL)


    SIGNATURE
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


     
    ENGENE HOLDINGS INC.
     
     
    Date: June 10, 2025
    By:
     /s/ Ronald H. W. Cooper
     
    Name: Ronald H. W. Cooper
     
    Title: Chief Executive Officer


    Get the next $ENGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ENGN

    DatePrice TargetRatingAnalyst
    2/18/2025$26.00Overweight
    Piper Sandler
    2/14/2025$34.00 → $7.00Buy → Neutral
    UBS
    12/23/2024$25.00Buy
    H.C. Wainwright
    11/27/2024$23.00Outperform
    Raymond James
    11/18/2024$18.00Mkt Outperform
    JMP Securities
    8/28/2024$30.00Outperform
    Oppenheimer
    4/22/2024$30.00Overweight
    Wells Fargo
    4/15/2024$34.00Buy
    Guggenheim
    More analyst ratings

    $ENGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

      Additional preliminary data from ongoing LEGEND study of detalimogene in pivotal cohort of BCG-unresponsive NMIBC with CIS anticipated in 2H 2025 Biologics License Application (BLA) filing planned for mid-2026 remains on track EMA Scientific Advice completed; Indicated data could be suitable for a Contingent Marketing Authorization Application Cash and marketable securities of $251.5 million expected to provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, or "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the second quarter ended April 30, 2025, and provided a business update. "We have seen strong

      6/12/25 8:00:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene Announces the Resignation of its Chief Medical Officer

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, announced today that Dr. Raj Pruthi resigned from his role as Chief Medical Officer on June 3, 2025. Dr. Pruthi's resignation as Chief Medical Officer will take effect on June 16, 2025. He will be supporting the organization to ensure an orderly transition of his responsibilities before he departs. The Company intends to reallocate Dr. Pruthi's responsibilities to the Company's other urology and clinical experts. The Company thanks Dr. Pruthi for his dedication and service and wishes him the best in his future endeavors. About enGene enGene is a clinical-stage biotechnology company mainstreaming g

      6/4/25 8:30:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene to Present at the Jefferies Global Healthcare Conference

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference in New York City on Wednesday, June 4, 2025, at 11:05 a.m. ET. A live webcast of the presentation can be accessed under the "Investors" section of the enGene website at www.engene.com and will be archived there for 90 days. About enGene enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene's lea

      5/29/25 8:00:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENGN
    Financials

    Live finance-specific insights

    See more
    • enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

      Additional preliminary data from ongoing LEGEND study of detalimogene in pivotal cohort of BCG-unresponsive NMIBC with CIS anticipated in 2H 2025 Biologics License Application (BLA) filing planned for mid-2026 remains on track EMA Scientific Advice completed; Indicated data could be suitable for a Contingent Marketing Authorization Application Cash and marketable securities of $251.5 million expected to provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, or "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the second quarter ended April 30, 2025, and provided a business update. "We have seen strong

      6/12/25 8:00:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene Reports First Quarter 2025 Financial Results and Provides Business Update

      Additional preliminary data from ongoing LEGEND study of detalimogene in BCG-unresponsive NMIBC with CIS, including pivotal cohort, anticipated in 2H 2025 Biologics License Application (BLA) filing planned for mid-2026 remains on track Cash and marketable securities of $272.8 million expected to provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, or "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2025, and provided a business update. "With the expansion of LEGEND study sites into Europe and Asia, enrollment in our pivotal cohort continues to track in-line with our pl

      3/10/25 4:05:00 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene Reports Full Year 2024 Financial Results and Provides a Business Update

      BLA filing for detalimogene in BCG-unresponsive NMIBC with CIS on track for mid-2026 All cohorts of the Phase 2 LEGEND study now recruiting under updated protocol Additional preliminary data from pivotal cohort anticipated in 2H 2025 Cash, cash equivalents and marketable securities of $297.9 million provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, or "enGene" or the "Company")), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder

      12/19/24 4:05:00 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Pott Amy

      3 - enGene Holdings Inc. (0001980845) (Issuer)

      5/29/25 5:30:57 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Pruthi Raj Som

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      1/31/25 4:46:11 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Strategy & Ops. Ofc Nichols Alexander Julian

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      1/31/25 4:44:27 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by enGene Holdings Inc.

      SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)

      11/14/24 5:48:15 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by enGene Holdings Inc.

      SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)

      11/14/24 5:05:21 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by enGene Holdings Inc.

      SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)

      11/14/24 7:53:57 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENGN
    SEC Filings

    See more
    • SEC Form 10-Q filed by enGene Holdings Inc.

      10-Q - enGene Holdings Inc. (0001980845) (Filer)

      6/12/25 8:08:08 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - enGene Holdings Inc. (0001980845) (Filer)

      6/12/25 8:05:52 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene Holdings Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - enGene Holdings Inc. (0001980845) (Filer)

      6/10/25 5:26:39 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ENGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Large owner Forbion Growth Opportunities Fund I Cooperatief U.A. bought $4,999,993 worth of shares (561,797 units at $8.90) (SEC Form 4)

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      11/1/24 4:15:08 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Forbion Growth Opportunities Fund I Cooperatief U.A. bought $3,012,674 worth of shares (470,633 units at $6.40) (SEC Form 4)

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      10/18/24 4:15:05 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Cooper Ronald Harold Wilfred bought $57,000 worth of shares (10,000 units at $5.70) (SEC Form 4)

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      10/1/24 8:02:44 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on enGene Holdings with a new price target

      Piper Sandler initiated coverage of enGene Holdings with a rating of Overweight and set a new price target of $26.00

      2/18/25 7:08:31 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene Holdings downgraded by UBS with a new price target

      UBS downgraded enGene Holdings from Buy to Neutral and set a new price target of $7.00 from $34.00 previously

      2/14/25 8:16:16 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on enGene Holdings with a new price target

      H.C. Wainwright initiated coverage of enGene Holdings with a rating of Buy and set a new price target of $25.00

      12/23/24 7:22:45 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENGN
    Leadership Updates

    Live Leadership Updates

    See more
    • enGene Names Amy Pott as Chief Global Commercialization Officer

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today announced the appointment of Amy Pott as Chief Global Commercialization Officer. In this role, Ms. Pott will serve as the Company's first dedicated executive for commercialization planning and execution, reporting to enGene's Chief Executive Officer, Ron Cooper. This appointment marks a significant milestone, as the Company expects to file a Biologics License Application (BLA) with the FDA in mid-2026 for detalimogene voraplasmid, its lead investigational agent in Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC), following the completion of the pivotal co

      5/28/25 7:30:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced the appointment of Joan Connolly as Chief Technology Officer (CTO) and member of the corporate leadership team. In addition, enGene Co-Founder and former CTO, Anthony Cheung, Ph.D., will transition to the role of Chief Scientific Officer, succeeding James Sullivan, MSc, Ph.D. Ms. Connolly's career spans

      10/21/24 8:45:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene Announces Appointment of Ron Cooper as Chief Executive Officer

      Ron Cooper succeeds Jason Hanson as Chief Executive Officer and Director Company also announces Dr. Raj Pruthi's promotion to Chief Medical Officer enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company"))), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive high-risk Non-Muscle Invasive Bladder Cancer (NMIBC), today announced that Ron Cooper has joined the Company as Chief Executive Officer and member of the Board of Directors, effective July 22, 2024. This transition follows a previously announced succession plan for Jason Hanson, who will remain in service to the Company as a strategi

      7/24/24 6:30:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care